Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Other Non-Current Assets (2020 - 2025)

Historic Other Non-Current Assets for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Q3 2025 value amounting to $596000.0.

  • Arcutis Biotherapeutics' Other Non-Current Assets fell 340.36% to $596000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $596000.0, marking a year-over-year decrease of 340.36%. This contributed to the annual value of $617000.0 for FY2024, which is 3329.73% down from last year.
  • Arcutis Biotherapeutics' Other Non-Current Assets amounted to $596000.0 in Q3 2025, which was down 340.36% from $596000.0 recorded in Q2 2025.
  • Arcutis Biotherapeutics' 5-year Other Non-Current Assets high stood at $1.5 million for Q1 2021, and its period low was $596000.0 during Q2 2025.
  • Its 5-year average for Other Non-Current Assets is $1.0 million, with a median of $925000.0 in 2023.
  • In the last 5 years, Arcutis Biotherapeutics' Other Non-Current Assets surged by 318085.11% in 2021 and then plummeted by 3329.73% in 2024.
  • Arcutis Biotherapeutics' Other Non-Current Assets (Quarter) stood at $1.5 million in 2021, then decreased by 19.97% to $1.2 million in 2022, then dropped by 25.04% to $925000.0 in 2023, then plummeted by 33.3% to $617000.0 in 2024, then dropped by 3.4% to $596000.0 in 2025.
  • Its Other Non-Current Assets was $596000.0 in Q3 2025, compared to $596000.0 in Q2 2025 and $617000.0 in Q1 2025.